Lawrence Fong
University of California, San Francisco · Cancer Immunotherapy Trials Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lawrence Fong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04064190 · Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionMedPacto, Inc. · withdrawn · Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma · principal investigator
- Ph2NCT03007719 · Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1Lawrence Fong · terminated · Bladder Cancer · principal investigator
- Ph2NCT02506114 · Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate CancerLawrence Fong · terminated · Prostatic Neoplasms · principal investigator
- Ph2NCT02451423 · Neoadjuvant Atezolizumab in Localized Bladder CancerLawrence Fong · completed · Carcinoma, Transitional Cell · principal investigator
- Ph2NCT01881867 · CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate CancerFred Hutchinson Cancer Center · completed · Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma · principal investigator
- Ph1NCT01823978 · Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate CancerBellicum Pharmaceuticals · completed · Castrate Resistent Prostate Cancer · principal investigator
- Ph2NCT01804465 · Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerUniversity of California, San Francisco · completed · Prostate Cancer · principal investigator
- Ph2NCT01530984 · Ipilimumab and GMCSF Immunotherapy for Prostate CancerLawrence Fong · withdrawn · Prostate Cancer · principal investigator
- Ph1NCT00305669 · GM-CSF Before Surgery in Treating Patients With Localized Prostate CancerUniversity of California, San Francisco · completed · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate CancerP50CA275741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2024 to 2026 · $451,950 awarded in 2026Same name and institution; not confirmed by an ID
- Cancer Immunology and Immunotherapy ProgramP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2023 to 2024 · $183,261 awarded in 2024Same name and institution; not confirmed by an ID
- Combining immunotherapy with molecularly targeted radiation therapyR01CA276785 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2023 · $663,343 awarded in 2023Same name and institution; not confirmed by an ID
- Precision targeting of T cell cytotoxicity with PETR01CA258297 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2021 to 2023 · $635,683 awarded in 2023Same name and institution; not confirmed by an ID
- Mechanisms of Exosome Driven Immunoregulation of Cancer ProgressionU01CA244452 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2019 to 2022 · $39,956 awarded in 2022Same name and institution; not confirmed by an ID
- Determinants of prostate cancer sensitivity to PD-1 blockadeR01CA223484 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2018 to 2021 · $368,288 awarded in 2021Same name and institution; not confirmed by an ID
- Immunotherapy of human bladder cancerR01CA194511 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2015 to 2019 · $351,691 awarded in 2019Grant number is on one of their registry trials
- Prostatitis and Prostate Cancer DevelopmentR01CA163012 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2012 to 2016 · $414,029 awarded in 2016Same name and institution; not confirmed by an ID
- Prostate Cancer ImmunotherapyR01CA136753 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2009 to 2013 · $292,312 awarded in 2013Same name and institution; not confirmed by an ID
- Dendritics Cell Immunotherapy for Colorectal CancerR01CA102303 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2004 to 2008 · $288,476 awarded in 2008Same name and institution; not confirmed by an ID
- DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCERK23CA082584 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1999 to 2003 · $124,826 awarded in 2003Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT01881867
- Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)P50CA097186 · NCI · FRED HUTCHINSON CANCER CENTER · PI Martin Edwin Gleave · fiscal years 2018 to 2026Named on NCT01881867
- U01CA154967RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01881867
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 73 PubMed records, and a shared surname and initials can bring in a namesake. All 73 on PubMed
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.N Engl J Med · 20172,822 citationsRCR 93.2
- 1,038 citationsRCR 31.3
- Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.Proc Natl Acad Sci U S A · 2001442 citationsRCR 7.6
- 403 citationsRCR 13.5
- 333 citationsRCR 8.2
- A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.Clin Cancer Res · 2007329 citationsRCR 6.2
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.Cancer Discov · 2020298 citationsRCR 11.1
- 272 citationsRCR 4.9
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.Clin Cancer Res · 2016246 citationsRCR 6.6
- Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.J Clin Oncol · 2010231 citationsRCR 4.7